Open AccessRanibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
Author(s) -
Daniel F Martin,
Maureen G. Maguire,
GuiShuang Ying,
Juan E. Grunwald,
Stuart L. Fine,
Glenn J. Jaffe
Publication year - 2011
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1102673
Subject(s) - macular degeneration , medicine , ranibizumab , bevacizumab , ophthalmology , clinical trial , chemotherapy
Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supporting data.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom